Safety of Apixaban for Cancer-Associated Thrombosis

Behnood Bikdeli; David Jiménez

doi:10.1055/a-1367-7830

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2021; 121(05): 547-551
DOI: 10.1055/a-1367-7830

Invited Editorial Focus

Safety of Apixaban for Cancer-Associated Thrombosis

Behnood Bikdeli

¹Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States

²Center for Outcomes Research and Evaluation (CORE), Yale University School of Medicine, New Haven, United States

³Cardiovascular Research Foundation (CRF), New York, United States

,

David Jiménez

⁴Respiratory Department, Ramón y Cajal Hospital, IRYCIS, Madrid, Spain

⁵Medicine Department, Universidad de Alcala, IRYCIS, Madrid, Spain

⁶CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

› Author Affiliations

Abstract

Full Text

References

References
1 Giustozzi M, Curcio A, Weijs B. et al. Variation in the association between antineoplastic therapies and venous thromboembolism in patients with active cancer. Thromb Haemost 2020; 120 (05) 847-856
2 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
3 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: Chest guideline and expert panel report. Chest 2016; 149 (02) 315-352
4 Konstantinides SV, Torbicki A, Agnelli G. et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069
5 Montroy J, Lalu MM, Auer RC. et al. The efficacy and safety of low molecular weight heparin administration to improve survival of cancer patients: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (05) 832-846
6 Akl EA, Kahale L, Barba M. et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; 7 (07) CD006650
7 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
8 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
9 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
10 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
11 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
12 Haykal T, Zayed Y, Deliwala S. et al. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized controlled trials. Thromb Res 2020; 194: 57-65
13 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
14 Ageno W, Vedovati MC, Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021; 121 (05) 616-624
15 Picker N, Lee AY, Cohen AT. et al. Anticoagulant treatment in cancer-associated venous thromboembolism: assessment of patient preferences using a discrete choice experiment (COSIMO study). Thromb Haemost 2021; 121 (02) 206-215
16 Weitz JI, Haas S, Ageno W. et al. Global anticoagulant registry in the field - venous thromboembolism (GARFIELD-VTE). Rationale and design. Thromb Haemost 2016; 116 (06) 1172-1179
17 Bikdeli B, Jimenez D, Hawkins M. et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
18 Cohen A, Keshishian A, Lee T. et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost 2021; 121 (03) 383-395